Concerns raised by FDA: are T cells malignant?
Welcome to the 59 new subscribers who joined our LinkedIn newsletter last week ?? If not done yet, subscribe to join the 4,936 fans of the Pick of the Week!
In recent years, CAR-T cell therapy has emerged as a groundbreaking treatment for various hematologic cancers.
But, now, the U.S. FDA has raised concerns about CAR-T, initiating an investigation into its potential risks.
The investigation was sparked after reports indicated a possible link between certain CAR-T cell treatments and the development of T cell malignancies in patients who received treatment.
So, what does this now mean for the future of CAR-T cell therapies?
To find out more, read the full article: "FDA CAR-T cell therapy warning: Are T cells malignant? "
?? More noteworthy articles from this week:
Drug discovery and development is a long, costly, and high-risk process that takes more than 10 to 15 years to complete - but now three major technologies could change this, helping to greatly speed up the process.
Alzheimer’s research has come a long way since the disease was first identified and, now - as treatments have been developed to reduce the harmful proteins in the brain that are associated with Alzheimer’s - vaccine trials are also underway that could eliminate these proteins.
As the holiday season approaches, there are plenty of biotech-themed gifts to get your friends and family this year, from glow-in-the-dark mushrooms to do-it-yourself (DIY) biology kits.
??Enjoying these articles??Never miss a single publication of Labiotech by becoming a part of our community!?Click here ?to join our mailing list.